Results

Celcuity Inc.

04/08/2021 | Press release | Distributed by Public on 04/08/2021 14:08

Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.